Brief: Gap Says Outlook FY Net Sales Up 1% To 2% Year-Over-Year Versus IBES Estimate Up 2.45%
BRIEF-Gap Says Outlook FY Net Sales Up 1% To 2% Year-Over-Year Versus IBES Estimate Up 2.45% May 28 (Reuters) - Gap Inc GAP.N:
GAP Q1 COMPARABLE SALES UP 2% VERSUS IBES ESTIMATE UP 3.06%
GAP Q1 NET SALES $3.50 BILLION VERSUS IBES ESTIMATE $3.52 BILLION
GAP Q1 ADJUSTED EPS $0.38 VERSUS IBES ESTIMATE $0.37
GAP OUTLOOK FY NET SALES UP 1% TO 2% YEAR-OVER-YEAR VERSUS IBES ESTIMATE UP 2.45%
GAP OUTLOOK Q2 NET SALES FLAT TO DOWN 1% YEAR-OVER-YEAR VERSUS IBES ESTIMATE UP 2.12%
GAP OUTLOOK Q2 GROSS MARGIN FLAT TO DOWN 50 BASIS POINTS
GAP: NET TARIFF BENEFIT EXPECTED TO BE CONCENTRATED IN Q2 Q3 BASED ON TIMING OF RECEIPTS
GAP OUTLOOK FY ADJUSTED DILUTED EPS ABOUT $2.30 TO $2.40 VERSUS IBES ESTIMATE $2.33
GAP: Q2 FISCAL 2026 DIVIDEND OF $0.175 PER SHARE
GAP: SEES ABOUT $80 MILLION OF NET TARIFF RELIEF TO GROSS PROFIT OPERATING INCOME OR ABOUT 50 BPS OF BENEFIT TO GROSS MARGIN OPERATING MARGIN IN FISCAL 2026
Source text: [ID:]
Further company coverage: GAP.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on The Gap
See all newsAmerican Eagle shares slump on flat margin outlook, weakness in namesake brand (updated)
American Eagle shares slide as flat margin outlook, weak core brand weigh
Street View: Gap shines despite Old Navy stumble
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics